&nbsp;

Oct 2023

Regimen

IDEL+RITU; IDEL(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria

New Drug Funding Program

Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia

Drugs Used:

idelalisib,

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

IRINRALT

Cancer Type:

Gastrointestinal,

Colorectal,

Esophagus,

Gastric / Stomach,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer

Drugs Used:

irinotecan,

raltitrexed

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

INOT

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Palliative

Funding:

New Drug Funding Program

Inotuzumab Ozogamicin (Outpatient) - Relapsed or Refractory Acute Lymphoblastic Leukemia

Drugs Used:

inotuzumab ozogamicin

Quick Link(s):

Regimen Monograph

Jul 2023

Drug

inotuzumab ozogamicin

Other Name(s): Besponsa®

Quick Link(s):

Jul 2023

Cancer facts

Increasing Food Literacy in Youth Can Reduce Chronic Diseases in Ontario

Jan 2023

Drug

irinotecan

Other Name(s): Camptosar®

Quick Link(s):

Apr 2023

Regimen

IBRU+RITU

Cancer Type:

Hematologic

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - In Combination with Rituximab for Previously Treated Waldenstrӧms Macroglobulinemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2025

Regimen

IBRU(MNT)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Drugs Used:

iBRUtinib (Unfunded)

Quick Link(s):

Regimen Monograph

May 2025

Regimen

IBRUVENE

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Drugs Used:

iBRUtinib (Unfunded),

venetoclax (Unfunded)

Quick Link(s):

Regimen Monograph

May 2025

Drug

iBRUtinib

Other Name(s): Imbruvica®

Quick Link(s):

Updated

Jun 2025

Regimen

IBRU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For relapsed and refractory Mantle Cell Lymphoma, according to clinical criteria

Drugs Used:

iBRUtinib